Amoy Diagnostics Co., Ltd. (SHE:300685)
China · Delayed Price · Currency is CNY 22.44
-0.08 (-0.36%)
Mar 19, 2026, 11:55 AM CST
Amoy Diagnostics Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,198 | 1,104 | 1,034 | 832.43 | 908.12 |
Other Revenue | - | 4.64 | 9.99 | 9.75 | 8.91 |
| 1,198 | 1,109 | 1,044 | 842.18 | 917.03 | |
Revenue Growth (YoY) | 8.00% | 6.27% | 23.91% | -8.16% | 25.90% |
Cost of Revenue | - | 181.34 | 176.92 | 153.44 | 147.19 |
Gross Profit | 1,198 | 927.61 | 866.58 | 688.74 | 769.84 |
Selling, General & Admin | - | 418.83 | 384.71 | 360.44 | 364.31 |
Research & Development | - | 216.11 | 203.22 | 174.53 | 156.12 |
Other Operating Expenses | 780.01 | 4.66 | 4.07 | 3.14 | 4.18 |
Operating Expenses | 780.01 | 650.35 | 597.12 | 545.1 | 534.79 |
Operating Income | 417.66 | 277.25 | 269.46 | 143.64 | 235.05 |
Interest Expense | - | -1.34 | -1.2 | -0.99 | -0.38 |
Interest & Investment Income | - | 26.58 | 19.17 | 6.11 | 5.59 |
Currency Exchange Gain (Loss) | - | 2.42 | 8.25 | 25.32 | -9.48 |
Other Non Operating Income (Expenses) | -6.43 | -18.45 | -0.33 | -2.08 | -0.48 |
EBT Excluding Unusual Items | 411.23 | 286.46 | 295.35 | 171.99 | 230.3 |
Gain (Loss) on Sale of Investments | - | -8.71 | -15.69 | 1.98 | 5.85 |
Gain (Loss) on Sale of Assets | - | -1.06 | -0.96 | 94.58 | -1.96 |
Asset Writedown | - | -0.06 | -0.04 | -0.61 | -0.27 |
Other Unusual Items | - | 13.26 | 16.19 | 18.15 | 18.06 |
Pretax Income | 411.23 | 289.88 | 294.86 | 286.08 | 251.98 |
Income Tax Expense | 53.34 | 35.02 | 33.37 | 21.79 | 12.95 |
Earnings From Continuing Operations | 357.89 | 254.86 | 261.48 | 264.29 | 239.02 |
Minority Interest in Earnings | - | - | - | -0.55 | 0.55 |
Net Income | 357.89 | 254.86 | 261.48 | 263.74 | 239.57 |
Net Income to Common | 357.89 | 254.86 | 261.48 | 263.74 | 239.57 |
Net Income Growth | 40.42% | -2.53% | -0.86% | 10.09% | 32.86% |
Shares Outstanding (Basic) | 398 | 398 | 396 | 394 | 399 |
Shares Outstanding (Diluted) | 398 | 398 | 396 | 394 | 399 |
Shares Change (YoY) | -0.14% | 0.51% | 0.65% | -1.41% | -0.36% |
EPS (Basic) | 0.90 | 0.64 | 0.66 | 0.67 | 0.60 |
EPS (Diluted) | 0.90 | 0.64 | 0.66 | 0.67 | 0.60 |
EPS Growth | 40.63% | -3.03% | -1.49% | 11.67% | 33.33% |
Free Cash Flow | - | 301.64 | 253.85 | 70.75 | 93.61 |
Free Cash Flow Per Share | - | 0.76 | 0.64 | 0.18 | 0.23 |
Dividend Per Share | - | 0.300 | 0.150 | 0.140 | 0.128 |
Dividend Growth | - | 100.00% | 7.14% | 9.55% | -7.99% |
Gross Margin | 100.00% | 83.65% | 83.05% | 81.78% | 83.95% |
Operating Margin | 34.87% | 25.00% | 25.82% | 17.06% | 25.63% |
Profit Margin | 29.88% | 22.98% | 25.06% | 31.32% | 26.13% |
Free Cash Flow Margin | - | 27.20% | 24.33% | 8.40% | 10.21% |
EBITDA | 463.65 | 323.25 | 322.24 | 191.46 | 271.49 |
EBITDA Margin | 38.71% | 29.15% | 30.88% | 22.73% | 29.61% |
D&A For EBITDA | 45.99 | 45.99 | 52.78 | 47.82 | 36.45 |
EBIT | 417.66 | 277.25 | 269.46 | 143.64 | 235.05 |
EBIT Margin | 34.87% | 25.00% | 25.82% | 17.06% | 25.63% |
Effective Tax Rate | 12.97% | 12.08% | 11.32% | 7.62% | 5.14% |
Revenue as Reported | - | 1,109 | 1,044 | 842.18 | 917.03 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.